Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Market Wrap: Cautious rebound in Europe after the drop in oil prices
Nvidia Goes to Space. SpaceX Is Building Satellites Powered by Its Chips
Morning Wrap: Strong Crypto, Weaker Nasdaq and Another Chapter in the US–Canada Trade War
Daily Summary: Modest declines ahead of Jackson Hole and Nvidia